Computing First.

Where drug discovery begins with computation, not trial-and-error.

MacroGene AI brings AI-plus-physics modelling to antibodies, peptides, nucleotides, and small molecules — delivering mechanistic clarity before a single experiment is run.

Explore Platform →Our Approach →

About Us

MacroGene AI Private Limited was founded in 2026 with a simple belief at its core: Computing First. We exist to replace trial-and-error discovery with predictive intelligence.

Antibodies
DNA / RNA
Peptides
Formulations
Small Molecules

Predictive intelligence for modern therapeutic discovery.

Our work is grounded in more than two decades of real R&D experience supporting discovery programs at Aragen Life Sciences, Zydus Lifesciences, and Sun Pharma Advanced Research Company Limited.

From humanization and epitope mapping to computational point-mutation studies that guided an antibody toward successful ADC development, this experience forms the scientific backbone of MacroGene AI.

Today, we operate as a hybrid platform-plus-services company with a strong emphasis on high-value computational services across biologics and chemistry.

Antibody Engineering

Epitope mapping, humanization, and ADC-oriented modelling.

Learn More →

DNA & RNA Systems

Nucleotide structural analysis and sequence-level optimization.

Learn More →

Drug Discovery Infrastructure

Protein structure modelling and molecular interaction analysis.

Learn More →

Peptide Design

Computational design and optimization of therapeutic peptides.

Learn More →

Small Molecule Discovery

Virtual screening, docking, and lead optimization for small molecules.

Learn More →

Our Team

Experienced computational scientists, chemists, and operations leaders driving cross-disciplinary drug discovery and platform development.

Sairam Kalapatapu
Founder & Director

Sairam Kalapatapu

Founder-Director

Brings 22 years of industry experience in computer-aided drug design and computational modelling across small molecules, biologics, and oligonucleotides. Career spans leading R&D organizations including Aragen Life Sciences, Zydus Lifesciences, and Sun Pharma Advanced Research Company Limited. Expert in hit identification, lead optimization, antibody humanization, epitope mapping, and mechanistic modelling. Authored 21 peer-reviewed publications and inventor on 6 patents. Serves on the Board of Directors at Anveta Therapeutics and scientific consultant to Anveta Therapeutics and OmGene Lifesciences.

View Profile →
Chetan Puri

Chetan Puri

Computational Chemist & Synthetic Chemistry Advisor

Chetan Puri is a gold medalist in synthetic organic chemistry and a computational chemist with deep expertise in molecular modelling, small‑molecule design, and advanced chemical synthesis. He evolved from hands‑on synthetic chemistry to leading computational workflows, contributing to discovery programs through docking, virtual screening, molecular dynamics, and homology modelling. He collaborates effectively across multidisciplinary scientific teams, bringing clarity, precision, and strong scientific judgment to discovery programs. Chetan also brings operational and infrastructure strengths through Red Hat System Administration certification and experience managing Linux‑based servers, enabling efficient handling of computational pipelines and modelling environments.

View Profile →
Supriya Pradhan

Supriya Pradhan

Computational Chemist & Synthetic Chemistry Advisor

Supriya Pradhan is a computational chemist and AI‑driven drug discovery professional with extensive experience across leading pharmaceutical and life sciences organizations. She has worked at the intersection of chemistry, biology, and machine learning, contributing to research programs involving small molecules, peptides, and antibody therapeutics. Her expertise spans molecular modelling, molecular dynamics, protein–ligand docking, free‑energy methods, QSAR and machine‑learning model development, and AI‑enabled predictive systems for modern drug discovery. With a strong foundation in both synthetic and computational chemistry, Supriya has also contributed to next‑generation cheminformatics solutions for predictive retrosynthesis and reaction‑condition optimization. She brings scientific depth, innovation‑driven thinking, and practical execution to multidisciplinary teams, helping build scalable AI‑powered solutions for contemporary biotech and healthcare research.

View Profile →
Vijayalakshmi Vadlamannati

Vijayalakshmi Vadlamannati

Head- Finance & Business Development

Vijayalakshmi Vadlamannati is a finance and accounting professional with a strong analytical foundation built on a Master of Commerce, an MBA in Finance, and an Advanced Diploma in Mathematics from Osmania University. She brings disciplined financial judgment across budgeting, cost control, audit coordination, and financial planning, supported by deep numerical rigor and a structured, methodical working style. She also has extensive experience teaching commerce and mathematics in India and East Africa, strengthening her clarity in communication and ability to simplify complex financial concepts. She combines financial acumen, mathematical rigor, and a calm, structured working style suited for finance‑controller responsibilities.

View Profile →
Sreekanth Devalraju

Sreekanth Devalraju

Legal-Scientific Expert

Dr. Sreekanth Devalraju is a techno‑legal specialist with deep expertise in legal drafting, compliance management, intellectual property strategy, and business advisory functions. With over 14 years of experience in entrepreneurial administration and corporate legal consulting, he has supported organizations across nutraceuticals, biotechnology, and medical instrumentation by negotiating business transactions, resolving legal matters, and securing IP rights. His academic background spans a Ph.D. in Animal Sciences, an LL.B., a PG Diploma in Patent Law, an M.Sc. in Biotechnology, and advanced qualifications in business law, reflecting a multidisciplinary command of science, law, and regulatory frameworks.

View Profile →

Our clients include biotech startups, mid-to-large pharma teams, academic groups, and investors seeking mechanistic clarity. We speak the language of science, but with a commercial awareness of timelines, risk, and decision-making. Whether it’s identifying a membrane-proximal epitope that avoids a secreted receptor fragment, predicting developability issues before they surface, or ranking variants for experimental validation, our goal is always the same: deliver insights that accelerate real-world progress.

What We Do

We model biology with the depth of a wet lab — but at computational speed. Drug discovery still loses a lot of time on blind experimentation. We change that by screening vast design spaces in silico, ranking the most promising hits, and revealing the mechanistic reasons behind success or failure.

Epitope mapping & humanization

Molecular dynamics simulations

Sequence & variant design

Developability prediction

(stability, aggregation, liabilities)

ADC conjugation site modelling

Binding energy & affinity prediction

Peptide & nucleotide structural modelling

Small molecule interaction modelling

If it binds, folds, aggregates, mutates, or interacts — we model it.

Scientific Foundation

Our computational philosophy was shaped through real-world R&D experience across Aragen Life Sciences, Zydus Lifesciences, and Sun Pharma Advanced Research Company.

Mechanistic Modelling

Deep structural and energetic analysis for antibodies, peptides, and therapeutic biomolecules.

Learn More →

Variant & Mutation Studies

Computational mutation analysis and variant ranking to guide experimental validation and optimization.

Learn More →

Platform + Services Model

Hybrid computational infrastructure delivering scalable services for startups, pharma teams, academics, and investors.

Learn More →

We are building a future where computation becomes the first step in every discovery workflow.

Whether it is identifying membrane-proximal epitopes, predicting developability, modelling conjugation sites, or evaluating molecular energetics,MacroGene AI exists to make discovery faster, smarter, and more predictable.

Start a Collaboration →

Our Collaborators

Anveta TX
OmGene